Welcome!

News Feed Item

Diabetes: Battle for ascendancy escalates in expanding market - KOL Insight





 

 

 

NEW YORK, Aug. 27, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:



Diabetes: Battle for ascendancy escalates in expanding market – KOL Insight
http://www.reportlinker.com/p01601323/Diabetes-Battle-for-ascendancy-escalates-in-expanding-market-–-KOL-Insight.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology


Diabetes is one of the few disease areas that has retained its market value despite the entry of generics, the rise in drug prices and prevalence of the disease has allowed drug sales to soar to a worldwide value of $34.1 billion in 2012. While barriers to entry remain high with added scrutiny over cardiovascular and other safety risks, evident by Tresiba's (insulin degludec; Novo Nordisk) recent US failure, the exponential market growth makes diabetes one of the most attractive opportunities in Pharma.

Competition in the major drug segments are intense with Sanofi's basal insulin Lantus (insulin glargine), Novo's prandial insulin NovoRapid/NovoLog (insulin aspart), Merck's DPP-IV Januvia (sitagliptin), and Novo's GLP-1 Victoza (liraglutide) leading the way in their respective classes with best in class efficacy and safety. In addition to these clinical advantages, more convenient administration devices and strong marketing has helped them stand out from the competition.

While Novo Nordisk, Sanofi and Merck look set to protect their franchises with exciting pipeline therapies, Key Opinion Leaders interviewed by FirstWord note that there are a number of unmet needs in diabetes treatment and management. Companies that can address these needs and differentiate their products from existing players will see significant traction in this lucrative indication. This is evident from the successful launches of the novel SGLT-2 inhibitors- Invokana (canagliflozin; Johnson & Johnson/Mitsubishi Tanabe) and Forxiga (dapagliflozin; Bristol-Myers Squibb/AstraZeneca), in the US and EU. In addition, therapies showing significant incremental advances also have potential to usurp market share from the gold standard treatments.

'Therapy Trends: Diabetes' is compiled from exclusive, in-depth interviews with the world's leading Key Opinion Leaders in diabetes. It identifies and analyses the major factors, advances and trends currently influencing the diabetes treatment landscape. The report focuses on late-stage pipeline products, and how these could modify future Diabetes management.

FirstWord selected the KOLs for this Therapy Trends report based on their level of engagement and influence within the diabetes disease area, and their scientific standing and clinical experience. Our unique KOL scoring system identifies those thought leaders with the greatest insight into how diabetes clinical research will shape the future market.


Key Benefits

Diabetes: Battle for ascendancy escalates in expanding market examines the most prominent insights gained from the field's key opinion leaders. The results of FirstWord's research and analysis will help you to:
- Comprehend the current trends driving and shaping the global diabetes market

- Understand the future landscape and how new drug classes will fit into the treatment algorithm

- Compare and contrast the clinical profile of the insulins, DPP-IV, GLP-1 and SGLT-2 classes and assess their competitive strengths and weaknesses

- Assess the commercial and clinical potential of the next generation pipeline drugs, biosimilars, and existing therapies.

- Appreciate KOL calls for novel therapies and understand the commercial threat and opportunity for current products.

- Develop positioning strategies based on KOL insight

- Identify critical areas of unmet clinical need and opportunities for better disease management

- Evaluate the performance of companies with the most robust new product pipelines

- Recognise the key factors KOLs predict will drive future treatment trends


Critical questions answered

Diabetes: Battle for ascendancy escalates in expanding market answers key questions including:

- How might new therapies impact on the current first-line treatments?
- What are the current unmet needs and major challenges in diabetes treatment?
- What are the most promising late-stage classes in development?
- Which therapies are KOLs eagerly awaiting?
- How will the new therapies be positioned against each other in each of the disease segments?
- In what ways could players improve on existing therapies and what impact could this have on prescribing?
- How will treatment of diabetes look in the future?
- How do KOLs think the pricing environment is shaping the uptake of new diabetes treatments?
- What clinical research trends do KOLs predict for future diabetes therapies?


Diabetes Panel of Key Opinion Leaders

FirstWord selected the KOLs for this Therapy Trends report based on their level of engagement and influence within the Diabetes disease area, and their scientific standing and clinical experience. The Diabetes KOL panel assembled for this Therapy Trends research is drawn from North America and Europe:

- Associate Professor of Endocrinology, University of Michigan, Ann Arbor, MI.
- Assistant Professor, Division of General Internal Medicines, John Hopkins University, Baltimore, MD.
- Clinical Associate Professor of Medicine, Division of General Internal Medicines, University of Washington School of Medicine, Washington.
- Director of the Clinical Diabetes Center at the University Hospital Albert Einstein College of Medicine, a Division of Montefiori Medical Center, NY
- Associate Professor of Medicine, Endocrinology and Metabolism, Duke University, Durham, NC.
- Professor of Endocrinology and Metabolic Diseases, University of Nantes; Head of the Internal Medicine, Endocrinology and Diabetes Department
- Honorary Consultant, Diabetes, University Hospital Leicester, Leicesteshire, UK
- Director, Endocrinology, Diabetes and Clinical Nutrition, University Hospital, Basel, Switzerland.
- Professor, Professor of Medicine, Diabetes, Eberhard Karls University, University Hospital of Tuebingen, Germany.
- Professor of Medical Physiology, Department of Biomedical Sciences; Director of the Research Cluster for Diabetes and Obesity; Vice Chairman, Faculty of Health Sciences, University of Copenhagen, Denmark.
- Head, Diabeteszentrum Bad Lauterberg, Harz, Germany.
- Professor John Wilding, MD, Head of the Department of Obesity and Endocrinology, University of Liverpool, UK.


Future Event Updates

Dynamic clinical sectors develop. New product approvals/launches, extended indications or unexpected late-stage research failures/withdrawals can have a major impact on the treatment options for clinicians and performance of companies. What does such an event mean for stakeholders?
FirstWord's Therapy Trends Future Event Updates keep you one step ahead. As soon as a significant event has been identified we contact our KOL panelists to get their perspective of the event and what it means. This data is incorporated into the report and re-issued so the event can be seen in its wider market context.
This valuable service is included in the purchase price of the report and is provided for 12 months. You will receive fresh analysis every time a major market event breaks and a fully updated report will be delivered by to you one our consultants within days of each event's occurrence.
Whatever the event, Therapy Trends has the contacts, resources and knowledge to keep you up to date with what the latest market movements mean.


Methodology

This report provides a qualitative overview of the current and future diabetes market. Information was gathered from telephone interviews held with twelve key opinion leaders (KOLs), from across the major diabetes markets, including France, Germany, Italy, the UK and the US. These regions were selected because they contain many of the largest global markets for the pharmaceutical industry, and also influence the dynamics of Pharma markets in other countries.
In order to critically select Key Opinion Leaders (KOLs) a number of parameters were considered including their clinical experience, scientific publications, involvement with Pharma, involvement in clinical trials, and record of presenting at high profile international conferences.
Subjects covered in the interviews included future diagnostic and therapeutic strategies for diabetes, the future of diabetes drug classes, and new drugs entering the market. These leading KOLs also gave their views on current research, the usefulness of existing diabetes drug classes, the cost of newer drugs and other concerns in the therapy area.



Executive summary

Introduction

Methodology

Current diabetes marketplace

Diabetes overview
Diabetes definition
Diabetes segmentation
Epidemiology
Aetiology
Risk factors
Symptoms
Complications of diabetes
Diagnosis
Diabetes treatment
Current treatment landscape
Reimbursement of key diabetes brands
Current marketed therapies
Basal insulins
Prandial insulins
Premixed insulins
Dipeptidyl Peptidase-IV (DPP-IV) inhibitors
Glucagon-like peptide-1 (GLP-1) agonists/analogues
Sodium-glucose co-transporter-2 (SGLT-2) inhibitors
Thiazolidinediones (TZD)
Other non-insulin anti-diabetics
Pipeline therapies
Pipeline basal insulins
Pipeline prandial insulins
Pipeline dipeptidyl peptidase-IV (DPP-IV) inhibitors
Pipeline glucagon-like peptide-1 (GLP-1) agonists/analogues
Pipeline sodium-glucose co-transporter 2 (SGLT-2) inhibitors
Other pipeline non-insulin anti-diabetics
Treatment focus
Unmet needs in type 1 diabetes
Unmet needs in type 2 diabetes
Current treatment algorithm- Type2 diabetes
Future treatment algorithm
Future developments in Diabetes

KOL biographies





To order this report:
Pathology Industry:
Diabetes: Battle for ascendancy escalates in expanding market – KOL Insight

__________________________

Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
UpGuard has become a member of the Center for Internet Security (CIS), and will continue to help businesses expand visibility into their cyber risk by providing hardening benchmarks to all customers. By incorporating these benchmarks, UpGuard's CSTAR solution builds on its lead in providing the most complete assessment of both internal and external cyber risk. CIS benchmarks are a widely accepted set of hardening guidelines that have been publicly available for years. Numerous solutions exist t...
A critical component of any IoT project is what to do with all the data being generated. This data needs to be captured, processed, structured, and stored in a way to facilitate different kinds of queries. Traditional data warehouse and analytical systems are mature technologies that can be used to handle certain kinds of queries, but they are not always well suited to many problems, particularly when there is a need for real-time insights.
We're entering the post-smartphone era, where wearable gadgets from watches and fitness bands to glasses and health aids will power the next technological revolution. With mass adoption of wearable devices comes a new data ecosystem that must be protected. Wearables open new pathways that facilitate the tracking, sharing and storing of consumers’ personal health, location and daily activity data. Consumers have some idea of the data these devices capture, but most don’t realize how revealing and...
"Software-defined storage is a big problem in this industry because so many people have different definitions as they see fit to use it," stated Peter McCallum, VP of Datacenter Solutions at FalconStor Software, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Unless your company can spend a lot of money on new technology, re-engineering your environment and hiring a comprehensive cybersecurity team, you will most likely move to the cloud or seek external service partnerships. In his session at 18th Cloud Expo, Darren Guccione, CEO of Keeper Security, revealed what you need to know when it comes to encryption in the cloud.
Actian Corporation has announced the latest version of the Actian Vector in Hadoop (VectorH) database, generally available at the end of July. VectorH is based on the same query engine that powers Actian Vector, which recently doubled the TPC-H benchmark record for non-clustered systems at the 3000GB scale factor (see tpc.org/3323). The ability to easily ingest information from different data sources and rapidly develop queries to make better business decisions is becoming increasingly importan...
StackIQ has announced the release of Stacki 3.2. Stacki is an easy-to-use Linux server provisioning tool. Stacki 3.2 delivers new capabilities that simplify the automation and integration of site-specific requirements. StackIQ is the commercial entity behind this open source bare metal provisioning tool. Since the release of Stacki in June of 2015, the Stacki core team has been focused on making the Community Edition meet the needs of members of the community, adding features and value, while ...
Using new techniques of information modeling, indexing, and processing, new cloud-based systems can support cloud-based workloads previously not possible for high-throughput insurance, banking, and case-based applications. In his session at 18th Cloud Expo, John Newton, CTO, Founder and Chairman of Alfresco, described how to scale cloud-based content management repositories to store, manage, and retrieve billions of documents and related information with fast and linear scalability. He addres...
You think you know what’s in your data. But do you? Most organizations are now aware of the business intelligence represented by their data. Data science stands to take this to a level you never thought of – literally. The techniques of data science, when used with the capabilities of Big Data technologies, can make connections you had not yet imagined, helping you discover new insights and ask new questions of your data. In his session at @ThingsExpo, Sarbjit Sarkaria, data science team lead ...
Extracting business value from Internet of Things (IoT) data doesn’t happen overnight. There are several requirements that must be satisfied, including IoT device enablement, data analysis, real-time detection of complex events and automated orchestration of actions. Unfortunately, too many companies fall short in achieving their business goals by implementing incomplete solutions or not focusing on tangible use cases. In his general session at @ThingsExpo, Dave McCarthy, Director of Products...
Ixia (Nasdaq: XXIA) has announced that NoviFlow Inc.has deployed IxNetwork® to validate the company’s designs and accelerate the delivery of its proven, reliable products. Based in Montréal, NoviFlow Inc. supports network carriers, hyperscale data center operators, and enterprises seeking greater network control and flexibility, network scalability, and the capacity to handle extremely large numbers of flows, while maintaining maximum network performance. To meet these requirements, NoviFlow in...
"delaPlex is a software development company. We do team-based outsourcing development," explained Mark Rivers, COO and Co-founder of delaPlex Software, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
WebRTC is bringing significant change to the communications landscape that will bridge the worlds of web and telephony, making the Internet the new standard for communications. Cloud9 took the road less traveled and used WebRTC to create a downloadable enterprise-grade communications platform that is changing the communication dynamic in the financial sector. In his session at @ThingsExpo, Leo Papadopoulos, CTO of Cloud9, discussed the importance of WebRTC and how it enables companies to focus...
The competitive landscape of the global cloud computing market in the healthcare industry is crowded due to the presence of a large number of players. The large number of participants has led to the fragmented nature of the market. Some of the major players operating in the global cloud computing market in the healthcare industry are Cisco Systems Inc., Carestream Health Inc., Carecloud Corp., AGFA Healthcare, IBM Corp., Cleardata Networks, Merge Healthcare Inc., Microsoft Corp., Intel Corp., an...
Is your aging software platform suffering from technical debt while the market changes and demands new solutions at a faster clip? It’s a bold move, but you might consider walking away from your core platform and starting fresh. ReadyTalk did exactly that. In his General Session at 19th Cloud Expo, Michael Chambliss, Head of Engineering at ReadyTalk, will discuss why and how ReadyTalk diverted from healthy revenue and over a decade of audio conferencing product development to start an innovati...